Repaglinida [Inn-Spanish]
Categoria
Repaglinida [Inn-Spanish] Marchi, Repaglinida [Inn-Spanish] Analoghi
Repaglinida [Inn-Spanish] Marchi miscela
Repaglinida [Inn-Spanish] Formula chimica
C27H36N2O4
Repaglinida [Inn-Spanish] RX link
http://www.rxlist.com/cgi/generic/prandin.htm
Repaglinida [Inn-Spanish] FDA foglio
Repaglinida [Inn-Spanish] DMS (foglio di materiale di sicurezza)
Repaglinida [Inn-Spanish] Sintesi di riferimento
W. Grell et al. Int. PCT. pat. Appl. WO 93 00337
Repaglinida [Inn-Spanish] Peso molecolare
452.586 g/mol
Repaglinida [Inn-Spanish] Temperatura di fusione
130-131 oC
Repaglinida [Inn-Spanish] H2O Solubilita
Nessuna informazione disponibile
Repaglinida [Inn-Spanish] Stato
Solid
Repaglinida [Inn-Spanish] LogP
5.798
Repaglinida [Inn-Spanish] Forme di dosaggio
Compressa
Repaglinida [Inn-Spanish] Indicazione
Per il trattamento del diabete mellito di tipo II.
Repaglinida [Inn-Spanish] Farmacologia
La repaglinide è un orale di glucosio nel sangue farmaco che riduce della classe meglitinide utilizzato nella gestione del diabete di tipo 2 (noto anche come diabete non insulino-dipendente o NIDDM mellito). Repaglinide abbassa i livelli di glucosio nel sangue stimolando il rilascio di insulina dal pancreas. Questa azione è dipende dal funzionamento delle cellule beta nelle isole pancreatiche. Rilascio di insulina glucosio-dipendente è e diminuisce a basse concentrazioni di glucosio.
Repaglinida [Inn-Spanish] Assorbimento
Rapido (biodisponibilità è del 56%)
Repaglinida [Inn-Spanish] Tossicita
LD50> 1 g / kg (ratto) (W. Grell)
Repaglinida [Inn-Spanish] Informazioni paziente
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Repaglinida [Inn-Spanish] Atto interessato organismi
Gli esseri umani e altri mammiferi
![Repaglinida_[Inn-Spanish]](/images/rx/APRD00439.gif)
